Cover Image

HARDBACK
$52.95



View/Hide Left Panel

monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $640 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $19.8 million for a PIV vaccine.

If a vaccine program were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $20,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $38,000. If only 10% of primiparas utilized the vaccine, the annualized present value of the cost per QALY gained is $50,000.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

Hall CB. Parainfluenza Viruses. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 1613–1624.

Henrickson K, Ray R, Belshe R. Parainfluenza Viruses. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1489–1496.


Karron RA, Wright PF, Newman FK, et al. A Live Human Parainfluenza Type 3 Virus Vaccine is Attenuated and Immunogenic in Healthy Infants and Children. The Journal of Infectious Diseases 1995; 172:1445–1450.


Ventura SJ, Martin JA, Mathews TJ, et al. Advance Report of Final Natality Statistics, 1994. Monthly Vital Statistics Report 1996; 44.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement